Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics of post-mortem brains in early and late-onset Alzheimer's disease: unraveling differential Aβ effects and potential AD biomarkers_3_4

ABSTRACT: Alzheimer’s disease (AD) is the most common form of neurodegeneration presented mainly as late-onset AD (LOAD), and in younger individuals early-onset AD (EOAD). The pathological hallmarks of AD are the hyperphosphorylated tau neurofibrillary tangles and the amyloid beta (Aβ) plaques. We examined changes in the proteome of post-mortem temporal cortex from individuals with EOAD and LOAD, and revealed that EOAD represents a more aggressive form of the disease. Notably, we observed up-regulation of AD biomarkers p-tau181, p-tau217, and p-tau23, and tau MTBR243, in AD tissues. Two abundant tau peptides phosphorylated at p-231/p-235 and p-231/p-235/p-237 were present largely in AD tissues, which may be developed as biomarkers. Aβ was detected in about half of the cognitively unimpaired elderly controls with subtle proteome changes that resembled in part the changes of biological processes in AD. This could indicate an early stage of neurodegeneration preceding clinical AD symptoms or represent an AD-resilient state.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

DISEASE(S): Alzheimer's Disease

SUBMITTER: Evangelia Thanou

LAB HEAD: Ka Wan Li

PROVIDER: PXD067114 | Pride | 2026-07-13

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	UP000005640_9606_original_Abeta_MaptIsoforms_additional.fasta	Fasta
	raw_data_part3.zip	Other
	samples.xlsx	Xlsx
	search_DIA-NN.tsv.zip	Tabular

Items per page:

1 - 4 of 4

Similar Datasets

Proteomics of post-mortem brains in early and late-onset Alzheimer's disease: unraveling differential Aβ effects and potential AD biomarkers_1

Project description:Alzheimer’s disease (AD) is the most common form of neurodegeneration presented mainly as late-onset AD (LOAD), and in younger individuals early-onset AD (EOAD). The pathological hallmarks of AD are the hyperphosphorylated tau neurofibrillary tangles and the amyloid beta (Aβ) plaques. We examined changes in the proteome of post-mortem temporal cortex from individuals with EOAD and LOAD, and revealed that EOAD represents a more aggressive form of the disease. Notably, we observed up-regulation of AD biomarkers p-tau181, p-tau217, and p-tau23, and tau MTBR243, in AD tissues. Two abundant tau peptides phosphorylated at p-231/p-235 and p-231/p-235/p-237 were present largely in AD tissues, which may be developed as biomarkers. Aβ was detected in about half of the cognitively unimpaired elderly controls with subtle proteome changes that resembled in part the changes of biological processes in AD. This could indicate an early stage of neurodegeneration preceding clinical AD symptoms or represent an AD-resilient state.

2026-07-13 | PXD066886 | Pride

Proteomics of post-mortem brains in early and late-onset Alzheimer's disease: unraveling differential Aβ effects and potential AD biomarkers_4

2026-07-13 | PXD067113 | Pride

Proteomics of post-mortem brains in early and late-onset Alzheimer's disease: unraveling differential Aβ effects and potential AD biomarkers_library

2026-07-13 | PXD066868 | Pride

Proteomics of post-mortem brains in early and late-onset Alzheimer's disease: unraveling differential Aβ effects and potential AD biomarkers_3

2026-07-13 | PXD067115 | Pride

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Project description:Alzheimer’s disease (AD) manifested before age 65 is commonly referred to as early-onset AD (EOAD). While the majority (> 90%) of EOAD cases are not caused by autosomal-dominant mutations in PSEN1, PSEN2, and APP, they do have a higher heritability (92–100%) than sporadic late-onset AD (LOAD, 70%). Although the endpoint clinicopathological changes, i.e., Aβ plaques, tau tangles, and cognitive decline, are common across EOAD and LOAD, the disease progression is highly heterogeneous. This heterogeneity, leading to temporally distinct age at onset (AAO) and stages of cognitive decline, may be caused by myriad combinations of distinct disease-associated molecular mechanisms. We and others have used transcriptome profiling in AD patient-derived neuron models of autosomal-dominant EOAD and sporadic LOAD to identify disease endotypes. Further, analyses of large postmortem brain cohorts demonstrate that only one-third of AD patients show hallmark disease endotypes like increased inflammation and decreased synaptic signaling. Areas of the brain less affected by AD pathology at early disease stages—such as the primary visual cortex—exhibit similar transcriptomic dysregulation as those regions traditionally affected and, therefore, may offer a view into the molecular mechanisms of AD without the associated inflammatory changes and gliosis induced by pathology. To this end, we analyzed AD patient samples from the primary visual cortex (19 EOAD, 20 LOAD) using transcriptomic signatures to identify patient clusters and disease endotypes. Interestingly, although the clusters showed distinct combinations and severity of endotypes, each patient cluster contained both EOAD and LOAD cases, suggesting that AAO may not directly correlate with the identity and severity of AD endotypes.

2022-10-12 | GSE203206 | GEO

Are Mouse Models a surrogate for human disease? A temporal, quantitative and molecular perspective.

Project description:It is unclear to what extent Tau molecular pathology in murine models reflect human Tauopathies. Nevertheless, mouse models that overexpress human mutant Tau (P301S and P301L) are widely used in studies of Tauopathies and Alzheimer’s Disease (AD). In this study, we perform an in-depth temporally and spatially resolved mass spectrometry-based proteomic analysis of P301S (hTau.P301S) and P301L (rTg(tauP301L)4510) mice as well as human patients with AD or frontotemporal dementia due to the P301L mutation, to identify differences and similarities between human AD, animal models and human P301L patients. Both mouse models and human P301L patients show progressive Tau accumulation driven by Tau phosphorylation during disease progression as also observed in early human AD. However, Tau ubiquitination and acetylation, important in human AD, are less or not represented in the mouse models or in P301L patients. Our analyses provide guidance regarding designing mechanistic studies and testing of Tau directed therapeutics.

2023-02-03 | PXD033965 | Pride

Properties of Alzheimer’s disease brain-derived tau aggregates define tau processing by human astrocytes

Project description:The templated misfolding of tau proteins accounts for tau pathology spread in Alzheimer’s disease (AD). Post-translational modifications, including phosphorylation at specific residues, are closely linked with tau seeding ability and clinical disease progression. This study investigates the role of astrocytes in tau spread, demonstrating that tau aggregates from post-mortem AD brain are internalized and processed by human astrocytes. Differences in tau internalization, clearance, and seeding were observed, potentially reflecting the molecular properties of tau. A direct relationship between tau handling by astrocytes and astrocyte responses was noted in transcriptomic data, highlighting dysregulated genes linked to pathological tau clearance pathways. To explore these differences, mass spectrometry was performed on both control and AD brain extracts, providing insights into the complex interplay between tau diversity and astrocyte responses in AD.

2025-05-07 | PXD056614 | Pride

Modeling early-onset sporadic Alzheimer’s disease using iPSC-derived neurons

Project description:Non-familial Alzheimer’s disease (AD) occurring before 65 years of age is commonly referred to as early-onset Alzheimer’s disease (EOAD) and constitutes ~5-6% of all Alzheimer’s disease (AD) cases. While EOAD exhibits the same clinicopathological changes such as amyloid plaques, neurofibrillary tangles (NFTs), brain atrophy, and cognitive decline as observed in the more prevalent late-onset AD (LOAD), EOAD patients tend to have more severe cognitive deficits, including visuospatial, language, and motor dysfunction. Patient-derived induced pluripotent stem cells (iPSCs) have been used to model and study penetrative, familial AD (FAD) mutations in APP, PSEN1, and PSEN2, but have been seldom used for sporadic forms of AD that display more heterogeneous disease manifestation. In this study, we sought to characterize iPSC-derived neurons from EOAD patients via RNA-sequencing. A modest difference in expression profiles between EOAD patients and non-demented control subjects resulted in a limited number of differentially expressed genes (DEGs). Based on this analysis, we provide evidence that iPSC-derived neuron model systems, likely due to the loss of EOAD-associated epigenetic signatures during the iPSC reprogramming, are not an ideal model system to study sporadic AD.

2023-11-21 | GSE231341 | GEO

Posttranslational modifications mediate the structural diversity of tauopathy strains

Project description:Tau aggregation is the defining pathological hallmark of tauopathies, but structural insights are revealing key differences between filaments across this class of disorders. Using cryo-electron microscopy, we identify a 107-residue fragment, K274-E380, which forms the insoluble core of tau filaments in the tauopathy corticobasal degeneration (CBD). This tau conformer is distinct from those identified in Alzheimer’s Disease (AD), Pick’s Disease, and Chronic Traumatic Encephalopathy, pointing towards a “one strain per disease” paradigm. Each disease-specific conformer can pack into multiple fibril subtypes and, despite similarities in secondary structure elements between tau filaments from CBD and AD, mass spectrometry revealed key differences in posttranslational modifications (PTMs). Given the abundance of lysine residues in the insoluble tau filament core in both CBD and AD, ubiquitination and acetylation are identified as key PTMs that compete to modify specific residues, which may ultimately determine filament morphology.

2020-02-14 | PXD016862 | Pride

Tau molecular diversity mediates clinical heterogeneity in Alzheimer’s disease

Project description:Alzheimer’s disease (AD) causes unrelenting, progressive cognitive impairments, but its course is heterogeneous, with a broad range of rates of cognitive decline. The spread of tau aggregates (neurofibrillary tangles) across the cerebral cortex parallels symptom severity. We hypothesized that the kinetics of tau spread may vary if the properties of the propagating tau proteins varied across individuals. We carried out biochemical, biophysical, and both cell- and animal-based bioactivity assays, and mass spectrometry, to characterize tau in 32 AD patients. We found striking patient-to-patient heterogeneity in the hyperphosphorylated species of soluble, oligomeric, seed-competent tau. Tau seeding activity correlates with the aggressiveness of the clinical disease, and some post-translational modification sites appear to be associated with both enhanced seeding activity and worse clinical outcomes, while others are not. These data suggest that different individuals with “typical” AD may have distinct biochemical features of tau. These data are consistent with the possibility that individuals with AD, much like cancer patients, may have multiple molecular drivers of an otherwise common phenotype, and emphasizes the potential for personalized therapeutic approaches for slowing clinical progression in AD.

2020-08-09 | PXD018855 | Pride